3 completed, 2 withdrawn, 1 recruiting, 1 terminated. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 3, Withdrawn 2, Recruiting 1, Terminated 1, Unknown 1 |
Follow Bumetanide: new trials by email Literature Review of Bumetanide trials Research Report on Bumetanide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure Bumetanide, intranasal 4mg - Heart Failure Congestive | Phase 4 | Withdrawn | Prisma Health-Upstate | 2026-01-21 | 2026-01-29 | |
| Diuretics and Volume Overload in Early CKD Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide) - Chronic Kidney Disease, Hypertension | Phase 4 | Completed | VA Office of Research and Development | 49 | 2023-02-01 | 2026-09-21 |
| Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial Low dose combination polydiuretic therapy, Comparator monotherapy empagliflozin - Heart Failure With Preserved Ejection Fraction | Phase 4 | Terminated | The George Institute | 3 | 2022-10-01 | 2024-11-21 |
| Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment UNa measurement after intravenous loop diuretic bolus, Intravenous acetazolamide 500 mg OD, Intravenous bumetanide TID - Acute Heart Failure, Diuretics Drug Reactions | Phase 4 | Completed | Vrije Universiteit Brussel | 107 | 2022-06-12 | 2026-09-11 |
| Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts Furosemide, Torsemide, Bumetanide - Heart Failure, Congestive | Phase 4 | Recruiting | Heart Center Research, LLC | 80 | 2021-07-08 | 2024-01-29 |
| Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg - HF - Heart Failure, Diabetes Mellitus | Phase 4 | Withdrawn | Northwestern University | 2021-01-08 | 2022-05-10 | |
| Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure Bumetanide 1 MG - Heart Failure, Congestive Heart Failure | Phase 4 | Unknown | Centro en Insuficiencia Cardiaca, Mexico | 40 | 2018-10-15 | 2018-10-17 |
| Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure Combination therapy with acetazolamide and low-dose loop diuretics, High-dose loop diuretics, Upfront therapy with oral spironolactone - Heart Failure | Phase 4 | Completed | Hasselt University | 34 | 2013-11-01 | 2019-05-21 |
Heart Failure (5) · Cardio-Renal Syndrome (1) · Diabetes Mellitus (1) · Edema (1) · Hypertension (1) · Renal Insufficiency, Chronic (1)
Centro en Insuficiencia Cardiaca, Mexico (1) · Hasselt University (1) · Heart Center Research, LLC (1) · Northwestern University (1) · Prisma Health-Upstate (1) · The George Institute (1) · VA Office of Research and Development (1) · Vrije Universiteit Brussel (1)
United States (4) · Belgium (2) · Australia (1) · Mexico (1)
Clare Arnott (1) · Frederik H Verbrugge, M.D.; Ph.D.; M.Sc. (1) · Frederik H. Verbrugge, M.D. Ph.D. (1) · Jason L Guichard, MD, PhD (1) · Jay Dinerman, MD (1) · Lucile P Gregg, MD MS (1) · Sadiya Khan, MD (1) · Wilfried Mullens, M.D. Ph.D. (1)
PMID 29587582, PMID 31074184, PMID 35460884, PMID 38447632
1IK2CX002368-01A1 (1)